CIAM
PVLA

Caitong International Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Caitong International Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4K Sell
180
-23
-11% -$2.4K ﹤0.01% 971
2025
Q4 		$21.2K Buy
+203
New +$17.3K 0.01% 973

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Caitong International Asset Management's PVLA Position: Q1 2026 in Review

Caitong International Asset Management reduced its Palvella Therapeutics (PVLA) stake by 11% in Q1 2026, selling an estimated $2.4K and leaving 180 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #971.

Caitong International Asset Management first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Caitong International Asset Management held 180 shares of Palvella Therapeutics worth $22.4K as of Q1 2026.
  • Caitong International Asset Management sold 23 Palvella Therapeutics shares in Q1 2026, an estimated $2.4K.
  • Palvella Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #971 holding.
  • Caitong International Asset Management first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.